Tempus AI Inc. saw its stock rise by 5.05% as it crossed above the 5-day SMA, reflecting positive market conditions.
The company recently launched its Paige Predict solution, which analyzes H&E whole slide images to predict the presence of 123 biomarkers, significantly enhancing testing efficiency in digital pathology. This innovation addresses the rising demand for next-generation sequencing and immunohistochemistry testing, allowing physicians to obtain actionable results quickly, thereby optimizing patient treatment plans. The launch marks a significant advancement for Tempus in precision medicine, solidifying its leadership position in the market.
This development not only showcases Tempus's commitment to technological innovation but also positions the company favorably in a competitive landscape, potentially driving further growth and market expansion.
Wall Street analysts forecast TEM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEM is 86.00 USD with a low forecast of 76.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast TEM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEM is 86.00 USD with a low forecast of 76.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
6 Hold
0 Sell
Moderate Buy
Current: 64.570
Low
76.00
Averages
86.00
High
105.00
Current: 64.570
Low
76.00
Averages
86.00
High
105.00
TD Cowen
Hold
downgrade
$88 -> $76
2026-01-07
Reason
TD Cowen
Price Target
$88 -> $76
AI Analysis
2026-01-07
downgrade
Hold
Reason
TD Cowen lowered the firm's price target on Tempus AI to $76 from $88 and keeps a Hold rating on the shares. The firm adjusted targets in the diagnostics group as part of a Q4 preview. It expects solid results and 2026 outlooks for the sector, saying strong fundamentals remain.
Canaccord
Kyle Mikson
Buy
downgrade
$95 -> $80
2025-12-22
Reason
Canaccord
Kyle Mikson
Price Target
$95 -> $80
2025-12-22
downgrade
Buy
Reason
Canaccord analyst Kyle Mikson lowered the firm's price target on Tempus AI to $80 from $95 and keeps a Buy rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes momentum in the sector which began in the second half of this year, can be maintained in 2026.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TEM
Unlock Now
JPMorgan
Casey Woodring
Neutral
downgrade
$85 -> $80
2025-12-15
Reason
JPMorgan
Casey Woodring
Price Target
$85 -> $80
2025-12-15
downgrade
Neutral
Reason
JPMorgan analyst Casey Woodring lowered the firm's price target on Tempus AI to $80 from $85 and keeps a Neutral rating on the shares. The firm updated models in the life science tools and diagnostics group.
BofA
Michael Ryskin
Neutral
downgrade
$90 -> $80
2025-12-15
Reason
BofA
Michael Ryskin
Price Target
$90 -> $80
2025-12-15
downgrade
Neutral
Reason
BofA analyst Michael Ryskin lowered the firm's price target on Tempus AI to $80 from $90 and keeps a Neutral rating on the shares. The firm is updating it price targets for Life Sciences & Diagnostic Tools stocks under its coverage, the analyst tells investors. Headwinds are expected to fade, and markets are expected to normalize in 2026, firm adds. The firm believes the biggest upside for the sector will be a return to spending by Biopharma, leading BofA to favor companies with higher exposure to research and development.
About TEM
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
